Sentynl Therapeutics has secured the first US approval of a therapy for a rare and fatal genetic condition called Menkes disease.
The company’s asset Zycubo was approved after being knocked back by …
Read More from Endpoints News
Sentynl gets the first US approval for rare copper absorption disease
